Dopamine agonists

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

167/211, 260/246

C07D 471/04 (2006.01) A61K 31/47 (2006.01) A61K 31/495 (2006.01) A61K 31/535 (2006.01)

Patent

CA 2021314

X-7071 -1- DOPAMINE AGONISTS The present invention relates to certain novel dopamine agonists which are useful in treating a variety of disorders including Parkinsonism, depression, hyper- tension, anxiety, glaucoma, sexual dysfunction and prolactin mediated disorders such as galactorrhea, amenorrhea, prolactinoma and the inhibition of post- partum lactation. D-2 dopamine agonists are known to have the ability to inhibit the secretion of prolactin. Accord- ingly, such compounds are useful in treating a variety of prolactin mediated disorders such as galactorrhea, amenorrhea, prolactinoma and the inhibition of post- partum lactation. Furthermore, such agonists have been found to favorably affect a wide variety of mammalian disorders including Parkinson's Syndrome, depression, hypertension, anxiety, glaucoma and sexual dysfunction. Given the wide variety of therapeutic uses for D-2 dopamine agonists any compound which can be shown to have such activity provides an important weapon in the treatment of a variety of disorders which commonly afflict the mammalian species.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Dopamine agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dopamine agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine agonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2080659

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.